📋 Tender Overview
The IKK classic announces that it will enter into non-exclusive discount agreements with all interested and suitable pharmaceutical companies for various active ingredients and combinations of active ingredients according to § 130a Abs. 8 SGB V under the Open-House procedure from 01/07/2026 to 30/06/2028, under the same non-negotiable conditions. The earliest contract start date is 01/07/2026, provided that the signed contract and all necessary evidence, self-declarations, and documents are received by IKK classic by 05/06/2026. Participation in the agreement is possible at any time within the specified period, but no later than 05/05/2028. Adalimumab, Adapalen 3 mg/g, Benzoylperoxid 25 mg/g, Aflibercept, Alglucosidase alfa, Bimatoprost, Biperiden, Brolucizumab, Budesonid, Dabrafenib, Dalteparin, Diazepam, Dimethylfumarat, Eisen, Epoetin alfa, Epoetin zeta, Etanercept, Filgrastim, Glibenclamid, Lercanidipin, Mepolizumab, Pegfilgrastim, Propranolol, Risperidon, Stiripentol, Tafluprost, Tafluprost und Timolol, Teriparatid, Tofacitinib, Trientin, Vitamine, Tocilizumab
